Next Generation Solutions
for Targeted Therapies
The OnkoGenetiks Fusion panel is used as an important source of biomarkers and therapeutic targets in various cancer types, and it provides detection of more than 75 fusions in 26 genes.
What is Fusion Analysis?
Fusion genes are hybrid genes that combine parts of two or more genes. İt can occur as a result of chromosomal rearrangements or abnormal transcription. İt have been shown to act as drivers of malignant transformation and progression in many types of cancer. The biological significance of fusion genes and their specificity to cancer cells have made them excellent targets for molecular therapy.
Fusion genes are also used as diagnostic and prognostic markers to confirm cancer diagnosis and monitor response to molecular treatments. Next Generation Sequencing (NGS) has enabled the systematic discovery of fusion genes in a wide variety of cancer types.
Why is OncoGenetiks Fusion?
Fusion genes are used as an important source of biomarkers and therapeutic targets in various types of cancer. More than 75 fusions in 26 genes are detected with the Onkogenetiks Fusion panel.
With Onkogenetiks Fusion panel;
- It can be informative about targeted therapies
- It can be used as a genetic marker to guide treatment by determining the target drug
- It can be helped diagnose certain types of cancer
General workflow of OnkoGenetiks Fusion Analysis:
The overall procedure starts with RNA extraction from FFPE tissue sample. After library construction and target enrichment with QIAseq Targeted DNA Panels, NGS is performed by using Illumina NextSeq 550Dx sequencing platform.
Analysis of raw sequencing data is carried out and detected variants can be interpreted with the Ingenuity®Variant Analysis (IVA) or QIAGEN Clinical Insight (QCI™) tools.